`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC., DR. REDDY’S LABORATORIES, INC.,
`
`and DR. REDDY’S LABORATORIES, LTD.
`
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`
`Patent Owner.
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2023-007241
`
`Patent No. 10,335,462
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPDATED LIST OF PETITIONER’S EXHIBITS
`
`
`
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current
`
`exhibit list.
`
`
`1 IPR2024-00009 (Dr. Reddy’s Laboratories) has been joined with this proceeding.
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT
`NO.
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`DESCRIPTION
`
`U.S. Patent No. 10,335,462
`
`Prosecution history excerpts for U.S. Patent No. 10,335,462
`
`Declaration of John Bantle, MD
`
`CV of John Bantle, MD
`
`Declaration of William J. Jusko, Ph.D.
`
`1006
`
`CV of William J. Jusko, Ph.D.
`
`1007
`
`Declaration of Paul Dalby, Ph.D.
`
`1008
`
`CV of Paul Dalby, Ph.D.
`
`1009
`
`Intentionally Left Blank
`
`1010
`
`Intentionally Left Blank
`
`1011 WO 2011/138421
`
`1012
`
`1013
`
`1014
`
`1015
`
`Lovshin, Incretin-Based Therapies for Type 2 Diabetes Mellitus, 5
`NATURE REV. ENDOCRINOLOGY 262 (2009)
`
`Clinical Trial No. NCT00696657
`
`Clinical Trial No. NCT00851773
`
`WO 2006/097537
`
`1016
`
`U.S. Patent Application Pub. No. US2007/0010424
`
`1017
`
`U.S. Patent No. 5,512,549
`
`1018
`
`1019
`
`Banting, The Internal Secretion of the Pancreas, 7 J. LAB.
`CLINICAL MED. 251 (1922)
`
`Bell, Hamster Preproglucagon Contains the Sequence of Glucagon
`and Two Related Peptides, 302 NATURE 716 (1983)
`
`- 1 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1020
`
`Bydureon prescribing information (Jan. 2012)
`
`1021
`
`Byetta prescribing information (Oct. 2009)
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`1030
`
`Drab, Incretin-Based Therapies for Type 2 Diabetes Mellitus:
`Current Status and Future Prospects, 30 PHARMACOTHERAPY 609
`(2010)
`
`Drucker, Enhancing Incretin Action for the Treatment of Type 2
`Diabetes, 26 DIABETES CARE 2929 (2003)
`
`Drucker, The Incretin System: Glucagon-Like Peptide-1 Receptor
`Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes,
`368 LANCET 1696 (2006)
`
`Glaesner, Engineering and Characterization of the Long-Acting
`Glucagon-Like Peptide-1 Analogue LY2189265, an Fc Fusion
`Protein, 26 DIABETES/METABOLISM RSCH. & REV. 287 (2010)
`
`HARRISON’S PRINCIPLES OF INTERNAL MED., Chapter 338 (Fauci et
`al. eds. 17th ed. 2008)
`
`Holst, Truncated Glucagon-like Peptide I, an Insulin-Releasing
`Hormone from the Distal Gut, 211 (2) FEBS LETTERS 169 (1987)
`
`Holst, Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl
`Peptidase IV in the Treatment of Type 2 Diabetes Mellitus, 4
`CURRENT OP. IN PHARMACOLOGY 589 (2004)
`
`Jimenez-Solem, Dulaglutide, a Long-Acting GLP-1 Analog Fused
`with an Fc Antibody Fragment for the Potential Treatment of Type
`2 Diabetes, 12 CURRENT OP. IN MOLECULAR THERAPEUTICS 790
`(2010)
`
`Kim, Effects of Once-Weekly Dosing of a Long-Acting Release
`Formulation of Exenatide on Glucose Control and Body Weight in
`Subjects with Type 2 Diabetes, 30 DIABETES CARE 1487 (2007)
`
`- 2 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1031
`
`1032
`
`1033
`
`DESCRIPTION
`
`Knudsen, GLP-1 Derivatives as Novel Compounds for the
`Treatment of Type 2 Diabetes: Selection of NN2211 for Clinical
`Development, 26 DRUGS OF THE FUTURE 677 (2001)
`
`Knudsen, Glucagon-like Peptide-1: The Basis of a New Class of
`Treatment for Type 2 Diabetes, 47 J. MED. CHEMISTRY 4128 (2004)
`
`Knudsen, Liraglutide, a GLP-1 Analogue to Treat Diabetes, in
`ANALOGUE-BASED DRUG DISCOVERY II (Fischer & Ganellin eds.
`2010)
`
`1034
`
`U.S. Patent No. 6,268,343 (“Knudsen patent”)
`
`1035
`
`Lund, Emerging GLP-1 Receptor Agonists, 16 EXPERT OP. ON
`EMERGING DRUGS 607 (2011)
`
`1036
`
`1037
`
`1038
`
`Mojsov, Insulinotropin: Glucagon-like Peptide I (7-37) Co-
`encoded in the Glucagon Gene is a Potent Simulator of Insulin
`Release in the Perfused Rat Pancreas, 79 J. CLINICAL
`INVESTIGATION 616 (1987)
`
`Nielsen, Pharmacology of Exenatide (Synthetic Exendin-4): A
`Potential Therapeutic for Improved Glycemic Control of Type 2
`Diabetes, 117 REGUL. PEPTIDES 77 (2004)
`
`Seino, Dose-Dependent Improvement in Glycemia with Once-Daily
`Liraglutide without Hypoglycemia or Weight Gain: A Double-
`Blind, Randomized, Controlled Trial in Japanese Patients with
`Type 2 Diabetes, 81 DIABETES RSCH. & CLINICAL PRACTICE 161
`(2008)
`
`1039
`
`Victoza, PHYSICIANS’ DESK REFERENCE (65th ed. 2010)
`
`1040
`
`Vilsbøll, Glucagon-Like Peptide-1 and Diabetes Treatment, 21
`INT’L DIABETES MONITOR 1 (2009)
`
`1041
`
`WO 03/002136
`
`1042
`
`WO 91/11457
`
`- 3 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1043
`
`U.S. Patent App. Pub. 2004/0102486
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`Rohatagi, Model-Based Development of a PPARγ Agonist,
`Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial
`Designs, 48 J. CLINICAL PHARMACOLOGY 1420 (2008)
`
`Shargel, APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS (5th
`ed. 2005)
`
`Yun, Pharmacokinetic and Pharmacodynamic Modelling of the
`Effects of Glimepiride on Insulin Secretion and Glucose Lowering
`in Healthy Humans, 31 J. CLINICAL PHARMACY & THERAPEUTICS
`469 (2006)
`
`Tamimi, Drug Development: From Concept to Marketing!, 113
`NEPHRON CLINICAL PRACTICE c125 (2009)
`
`FDA Guidance for Industry, Exposure-Response Relationships -
`Study Design, Data, Analysis, and Regulatory Applications (Apr.
`2003)
`
`International Conference on Harmonisation; Dose-Response
`Information to Support Drug Registration; Guideline; Availability,
`59 Fed. Reg. 55972 (Nov. 9, 1994) (“ICH 1994”)
`
`Garber, Efficacy of Metformin in Type II Diabetes: Results of a
`Double-Blind, Placebo-Controlled, Dose-Response Trial, 102 AM.
`J. MED. 491 (1997)
`
`Landersdorfer, Pharmacokinetic/Pharmacodynamic Modelling in
`Diabetes Mellitus, 47(7) CLINICAL PHARMACOKINETICS 417 (2008)
`
`Madsbad, An Overview of Once-Weekly Glucagon-Like Peptide-1
`Receptor Agonists—Available Efficacy and Safety Data and
`Perspectives for the Future, 13 DIABETES, OBESITY & METABOLISM
`394 (2011)
`
`- 4 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`1061
`
`1062
`
`1063
`
`DESCRIPTION
`
`Møller, Mechanism-Based Population Modelling for Assessment of
`L-Cell Function Based on Total GLP-1 Response Following an
`Oral Glucose Tolerance Test, 38 J. PHARMACOKINETICS &
`PHARMACODYNAMICS 713 (2011)
`
`Landersdorfer, Mechanism-Based Population Pharmacokinetic
`Modelling in Diabetes: Vildagliptin as a Tight Binding Inhibitor
`and Substrate of Dipeptidyl Peptidase IV, 73 BRIT. J. CLINICAL
`PHARMACOLOGY 391 (2011) (“Landersdorfer 2011a”)
`
`Landersdorfer, Mechanism-Based Population Modelling of the
`Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients
`with Type 2 Diabetes, 73 BRIT. J. CLINICAL PHARMACOLOGY 373
`(2011) “(Landersdorfer 2011b”)
`
`U.S. Patent No. 5,118,666
`
`WO 2011/073328
`
`Blonde, Comparison of Liraglutide Versus Other Incretin-Related
`Anti-Hyperglycaemic Agents, 14 (suppl. 2) DIABETES, OBESITY &
`METABOLISM 20 (2012)
`
`Murphy, Review of the Safety and Efficacy of Exenatide Once
`Weekly for the Treatment of Type 2 Diabetes Mellitus, 46 ANNALS
`OF PHARMACOTHERAPY 812 (2012)
`
`WO 2011/058193
`
`U.S. Patent App. Pub. No. 2011/0166321
`
`Zarin, The ClinicalTrials.gov Results Database—Update and Key
`Issues, 364 NEW ENGL. J. MED. 852 (2011)
`
`Kirillova, Results and Outcome Reporting in ClinicalTrials.gov,
`What Makes it Happen?, 7(6) PLOS ONE 1 (2012)
`
`- 5 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1064
`
`1065
`
`1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`1071
`
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`DESCRIPTION
`
`Monami, Effects of Glucagon-Like Peptide-1 Receptor Agonists on
`Body Weight: A Meta-Analysis, 2012 EXPERIMENTAL DIABETES
`RSCH. 1 (2012)
`
`Tasneem, The Database for Aggregate Analysis of
`ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical
`Specialty, 7(3) PLOS ONE 1(2012)
`
`Knudsen, Liraglutide: The Therapeutic Promise from Animal
`Models, 64(suppl 167) INT’L J. CLINICAL PRACTICE 4 (2010)
`(“Knudsen 2010b”)
`
`U.S. Patent No. 8,536,122
`
`U.S. Patent No. 8,129,343
`
`REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso
`R. Gennaro ed., 20th ed. 2000)
`
`Boylan, Parenteral Products, in MODERN PHARMACEUTICS (Gilbert
`S. Banker et al. eds., 3d ed. 1996)
`
`U.S. Patent No. 6,284,727
`
`U.S. Patent No. 5,164,366
`
`U.S. Patent No. 6,458,924
`
`WO 00/37098
`
`U.S. Patent No. 7,022,674
`
`ClinicalTrials.gov Background, CLINICALTRIALS.GOV,
`https://clinicaltrials.gov/ct2/about-site/background (last visited
`Mar. 10, 2023)
`
`Award: ClinicalTrials.gov,
`https://ash.harvard.edu/news/clinicaltrials.gov (last visited Mar. 10,
`2023)
`
`- 6 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1078
`
`U.S. Patent App. Pub. No. 2004/0102486
`
`1079
`
`1080
`
`NCT00167115, CLINICALTRIALS.GOV,
`https://www.clinicaltrials.gov/ct2/show/NCT00167115 (last visited
`Mar. 10, 2023)
`
`NCT01933490, CLINICALTRIALS.GOV,
`https://www.clinicaltrials.gov/ct2/show/NCT01933490 (last visited
`Mar. 10, 2023)
`
`1081
`
`Ozempic prescribing information (Oct. 2022)
`
`1082
`
`1083
`
`1084
`
`1085
`
`1086
`
`Scheduling Order, Novo Nordisk Inc. v. Rio Biopharmaceuticals
`Inc., No. 22-294 (CFC) (D. Del. June 30, 2022), ECF No. 22
`
`Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation,
`No. 3038 (MDL Aug. 5, 2022)
`
`EMA, ICH Topic S 7 A Safety Pharmacology Studies for Human
`Pharmaceuticals (June 2001)
`
`ACS Publications, https://pubs.acs.org/toc/jmcmar/47/17;
`https://pubs.acs.org/doi/10.1021/jm030630m
`
`“Last Update Posted” definition from ClinicalTrials.gov
`https://clinicaltrials.gov/ct2/show/NCT00696657
`
`1087
`
`Prosecution history excerpts for U.S. Patent No. 9,764,003
`
`1088
`
`1089
`
`1090
`
`Markman Hearing Transcript, In Re: Ozempic (Semaglutide) Patent
`Litigation, No. 22-MD-3038 (D. Del. July 13, 2023)
`
`Claim Construction Order, In Re: Ozempic (Semaglutide) Patent
`Litigation, No. 22-MD-3038 (D. Del. July 25, 2023), ECF No. 148
`
`Joint Claim Construction Brief, In Re: Ozempic (Semaglutide)
`Patent Litigation, No. 22-MD-3038 (D. Del. May 1, 2023), ECF
`No. 119
`
`- 7 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1091
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`1097
`
`1098
`
`1099
`
`1100
`
`1101
`
`DESCRIPTION
`
`Declaration of Shannon M. Bloodworth in Support of Motion for
`Pro Hac Vice Admission of Shannon M. Bloodworth
`
`Declaration of David L. Anstaett in Support of Motion for Pro Hac
`Vice Admission of David L. Anstaett
`
`Declaration of Bryan D. Beel in Support of Motion for Pro Hac
`Vice Admission of Bryan D. Beel
`
`Intentionally Left Blank
`
`Intentionally Left Blank
`
`Astrup, Effects of Liraglutide in the Treatment of Obesity: A
`Randomised, Double-Blind, Placebo-Controlled Study, 374
`LANCET 1606 (2009)
`
`Garber, Liraglutide Versus Glimepiride Monotherapy for Type 2
`Diabetes (LEAD-3 Mono): A Randomised, 52-Week, Phase III,
`Double-Blind, Parallel-Treatment Trial, 373 LANCET 473 (2009)
`
`Garber, Liraglutide, A Once-Daily Human Glucagon-Like Peptide
`1 Analogue, Provides Sustained Improvements in Glycaemic
`Control and Weight for 2 Years as Monotherapy Compared with
`Glimepiride in Patients with Type 2 Diabetes, 13 DIABETES
`OBESITY & METABOLISM 348 (2011)
`
`Garber, Long-Acting Glucagon-Like Peptide 1 Receptor Agonists,
`34 DIABETES CARE S279 (2011)
`
`Jose, Exenatide Once Weekly: Clinical Outcomes and Patient
`Satisfaction, 4 PATIENT PREFERENCE & ADHERENCE 313 (2010)
`
`Patent and Exclusivity List for: NDA No. N209637 (Semaglutide –
`Ozempic) in FDA’s Approved Drug Products with Therapeutic
`Equivalence Evaluations (Orange Book) (2024)
`
`- 8 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1102
`
`DESCRIPTION
`
`Rubio-Herrera, Impact of Treatment with GLP1 Receptor Agonists,
`Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting
`List for Bariatric Surgery, 11 BIOMEDICINES 2785 (2023)
`
`1103
`
`Highlights of Prescribing Information: Saxenda, Rev. 12/2014
`
`1104
`
`1105
`
`Vahl, Gut Peptides in the Treatment of Diabetes Mellitus, 13
`EXPERT OPINION ON INVESTIGATIONAL DRUGS 177 (2004)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity entry for NDA No. N022341
`(Liraglutide Recombinant (Victoza)) (2011)
`
`1106
`
`Highlights of Prescribing Information: Wegovy, Rev. 3/2024
`
`1107
`
`1108
`
`1109
`
`1110
`
`1111
`
`Patent and Exclusivity List for: NDA No. N215256 (Semaglutide –
`Wegovy) in FDA’s Approved Drug Products with Therapeutic
`Equivalence Evaluations (Orange Book) (2024)
`
`White, A Brief History of the Development of Diabetes
`Medications, 27 DIABETES SPECTRUM 82 (2014)
`
`Grunberger, Monotherapy with the Once-Weekly GLP-1 Analogue
`Dulaglutide for 12 Weeks in Patients with Type 2 Diabetes: Dose-
`Dependent Effects on Glycaemic Control in a Randomized,
`Double-Blind, Placebo-Controlled Study, 29 DIABETIC MEDICINE
`1260 (2012)
`
`Karagiannis, Subcutaneously Administered Tirzepatide vs
`Semaglutide for Adults with Type 2 Diabetes: A Systematic Review
`and Network Meta‑Analysis of Randomised Controlled Trials,
`DIABETOLOGIA (published online Apr. 13, 2024)
`
`Madsbad, Review of Head-to-Head Comparisons of Glucagon-Like
`Peptide-1 Receptor Agonists, 18 DIABETES OBESITY &
`METABOLISM 317 (2016)
`
`- 9 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1112
`
`1113
`
`1114
`
`1115
`
`Ostawal, Clinical Effectiveness of Liraglutide in Type 2 Diabetes
`Treatment in the Real-World Setting: A Systematic Literature
`Review, 7 DIABETES THERAPY 411 (2016)
`
`Skrivanek, Dose-Finding Results in an Adaptive, Seamless,
`Randomized Trial of Once-Weekly Dulaglutide Combined with
`Metformin in Type 2 Diabetes Patients (AWARD-5), 16 DIABETES
`OBESITY & METABOLISM 748 (2014)
`
`Buse, Liraglutide Once a Day Versus Exenatide Twice a Day for
`Type 2 Diabetes: A 26-Week Randomised, Parallel-Group,
`Multinational, Open-Label Trial (LEAD-6), 374 LANCET 39 (2009)
`
`Centers for Disease Control and Prevention National Diabetes
`Statistics Report
`https://www.cdc.gov/diabetes/data/statistics-report/index.html (last
`accessed May 1, 2024
`
`1116
`
`Highlights of Prescribing Information: Mounjaro, Rev. 5/2022
`
`1117
`
`1118
`
`Applah, My Best Friends Are Taking Ozempic. Can I Share My
`Disapproval?, New York Times (June 28, 2023)
`
`Novo Nordisk Company Announcement: Financial report for the
`period 1 January 2018 to 31 March 2018 (dated May 2, 2018)
`
`1119
`
`Highlights of Prescribing Information: Trulicity, Rev. 9/2014
`
`1120
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity entry for NDA No. N206321
`(Liraglutide Recombinant – Saxenda and Ozempic) (2018)
`
`1121
`
`U.S. Patent No. 8,114,833
`
`1122
`
`American Diabetes Association, Pharmacologic Approaches to
`Glycemic Treatment: Standards of Care in Diabetes-2023, 46
`DIABETES CARE S140 (2023)
`
`1123
`
`Intentionally Left Blank
`
`- 10 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1124
`
`1125
`
`1126
`
`1127
`
`1128
`
`1129
`
`GRADE Research Study Group, Glycemia Reduction in Type 2
`Diabetes — Glycemic Outcomes, 387 NEW ENG. J. MED. 1063
`(2022)
`
`Pi-Sunyer, A Randomized, Controlled Trial of 3.0 mg of Liraglutide
`in Weight Management, 373 NEW ENG. J. MED. 11 (2015)
`
`Pratley, One Year of Liraglutide Treatment Offers Sustained and
`More Effective Glycaemic Control and Weight Reduction
`Compared with Sitagliptin, Both in Combination with Metformin,
`in Patients with Type 2 Diabetes: A Randomised, Parallel-Group,
`Open-Label Trial, 65 INT’L J. CLINICAL PRACTICE 397 (2011)
`
`Memorandum Order, Novo Nordisk Inc. v. Mylan Pharmaceuticals
`Inc., No. 23-cv-00101 (D. Del. Mar. 25, 2024), ECF No. 126
`
`[Proposed] Claim Construction Order, Novo Nordisk Inc. v. Mylan
`Pharmaceuticals Inc., No. 23-cv-00101 (D. Del. Dec. 15, 2023),
`ECF No. 79
`
`CECIL TEXTBOOK OF MEDICINE, Chapters 233 (Obesity) and 242
`(Diabetes Mellitus) (Goldman et al. eds., 22nd ed. 2004)
`
`1130
`
`Novo Nordisk Annual Report 2011
`
`1131
`
`Novo Nordisk Form 6-K (Feb. 2, 2011)
`
`1132
`
`1133
`
`1134
`
`1135
`
`Amori, Efficacy and Safety of Incretin Therapy in Type 2 Diabetes,
`298 J. AM. MED. ASS’N 194 (2007)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity A-69 (37th ed. 2017)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity ADA 229-30 (39th ed. 2019)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity ADA 242 (40th ed. 2020)
`
`- 11 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1136
`
`1137
`
`1138
`
`1139
`
`HARRISON’S PRINCIPLES OF INTERNAL MEDICINE, Chapters 74
`(Biology of Obesity), 75 (Evaluation and Management of Obesity),
`and 338 (Diabetes Mellitus) (Fauci et al. eds., 17th ed. 2008)
`
`Bhansali, Historical Overview of Incretin Based Therapies, 58
`SUPPL. TO JAPI 10 (2010)
`
`Holst, The Incretin Approach for Diabetes Treatment, 53 DIABETES
`S197 (2004)
`
`Lorenz, Recent Progress and Future Options in the Development of
`GLP-1 Receptor Agonsists for the Treatment of Diabesity, 23
`BIOORGANIC & MED. CHEM. LETTERS 4011 (2013)
`
`1140
`
`Deposition transcript of Robin S. Goland (Apr. 9, 2024)
`
`1141
`
`1142
`
`1143
`
`1144
`
`1145
`
`Preuss, Basics of Renal Anatomy and Physiology, 13 RENAL
`FUNCTION 1 (1993)
`
`Radbill, Rationale and Strategies for Early Detection and
`Management of Diabetic Kidney Disease, 83 MAYO CLIN PROC. 12
`(2008)
`
`James, Early Recognition and Prevention of Chronic Kidney
`Disease, 375 LANCET 1296 (2010)
`
`Holz, Glucagon-Like Peptide-1 Synthetic Analogs: New
`Therapeutic Agents for Use in the Treatment of Diabetes Mellitus,
`10 CURRENT MED. CHEMISTRY 2471 (2003)
`
`Pyram, Chronic Kidney Disease and Diabetes, 71 MATURITAS 94
`(2012)
`
`1146
`
`49 AM. J. KIDNEY DISEASES S13 (2007)
`
`1147
`
`Vollenweider, Anti-Hypertensive and Natriuretic Effect of
`Glucagon-Like Peptide 1 in Dahl S Rats: A Novel Function for a
`Pleotrophic Hormone?, 21 J. HYPERTENSION 1079 (2003)
`
`- 12 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1148
`
`1149
`
`1150
`
`1151
`
`1152
`
`Yu, Antihypertensive Effect of Glucagon-Like Peptide 1 in Dahl
`Salt-Sensitive Rats, 21 J. HYPERTENSION 1125 (2003)
`
`Gutzwiller, Glucagon-Like Peptide 1 Induces Natriuresis in
`Healthy Subjects and in Insulin-Resistant Obese Men, 89 J.
`CLININCAL ENDOCRINOLOGY & METABOLISM 3055 (2004)
`
`Park, Long-Term Treatment of Glucagon-Like Peptide-1 Analog
`Exendin-4 Ameliorates Diabetic Nephropathy through Improving
`Metabolic Anomalies in db/db Mice, 18 J. AM. SOC’Y.
`NEPHROLOLOGY 1227 (2007)
`
`Liu, The Exenatide Analogue AC3174 Attenuates Hypertension,
`Insulin Resistance, and Renal Dysfunction in Dahl Salt-Sensitive
`Rats, 9 CARDIOVASCULAR DIABETOLOGY 32 (2010)
`
`Kodera, Glucagon-Like Peptide-1 Receptor Agonist Ameliorates
`Renal Injury Through its Anti-Inflammatory Action without
`Lowering Blood Glucose Level in a Rat Model of Type 1 Diabetes,
`54 DIABETOLOGIA 96 (2011)
`
`1153
`
`Edwards, GLP-1: Target for a New Class of Antidiabetic Agents?,
`97 J. ROYAL SOC’Y MED. 270 (2004)
`
`1154
`
`Zepbound® Prescribing Information (rev. March 2024)
`
`Bode, Patient-Reported Outcomes Following Treatment with the
`Human GLP-1 Analogue Liraglutide or Glimepiride in
`Monotherapy: Results from a Randomized Controlled Trial in
`Patients with Type 2 Diabetes, 12 DIABETES, OBESITY & METAB.
`604 (2010)
`
`Jacobsen, Effect of Renal Impairment on the Pharmacokinetics of
`the GLP-1 Analogue Liraglutide, 68 BR. J. CLINICAL
`PHARMACOLOGY 898 (2009)
`
`Davidson, Mild Renal Impairment and the Efficacy and Safety of
`Liraglutide, 17(3) ENDOCRINE PRACTICE 345 (2011)
`
`1155
`
`1156
`
`1157
`
`- 13 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1158
`
`1159
`
`1160
`
`1161
`
`1162
`
`1163
`
`1164
`
`1165
`
`1166
`
`1167
`
`DESCRIPTION
`
`Press Release, Semaglutide 1.0 mg Demonstrates 24% Reduction in
`the Risk of Kidney Disease-Related Events in People with Type 2
`Diabetes and Chronic Kidney Disease in the FLOW Trial (Mar. 5,
`2024)
`
`McGuire, Effects of Oral Semaglutide on Cardiovascular
`Outcomes in Individuals With Type 2 Diabetes and Established
`Atherosclerotic Cardiovascular Disease and/or Chronic Kidney
`Disease: Design and Baseline Characteristics of Soul, a
`Randomized Trial, 25 DIABETES OBESITY METABOLISM 1932
`(2023)
`
`Perkovic, Intensive Glucose Control Improves Kidney Outcomes in
`Patients With Type 2 Diabetes, 83 KIDNEY INT’L 3 (2013)
`
`Zeeuw, Proteinuria, a Target for Renoprotection in Patients With
`Type 2 Diabetic Nephropathy: Lessons From Renaal, 65 KIDNEY
`INT’L 6 (2004)
`
`Rizzo, Glucose Lowering and Anti-atherogenic Effects of Incretin-
`based Therapies: Glp-1 Analogues and Dpp-4-inhibitors, 18
`EXPERT OP. INVESTIGATIONAL DRUGS 1495 (2009)
`
`Gutzwiller, Glucagon-Like Peptide-1 Is Involved in Sodium and
`Water Homeostasis in Humans, 73 DIGESTION 2 (2006)
`
`Kanbay, Effect of Tirzepatide on Blood Pressure and Lipids: a
`Meta-analysis of Randomized Controlled Trials, 25 DIABETES
`OBESITY METABOLISM 3766–3778 (2023)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity ADA 258-59 (41st ed. 2021)
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations, Patent and Exclusivity ADA 258-59 (42d ed. 2022)
`
`First Amended Complaint, In Re: Ozempic (Semaglutide) Patent
`Litigation, No. 22-1040 (D. Del. Mar. 21, 2023), ECF No. 84
`
`- 14 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1168
`
`1169
`
`1170
`
`1171
`
`1172
`
`1173
`
`1174
`
`1175
`
`1176
`
`1177
`
`1178
`
`DESCRIPTION
`
`U.S. Patent No. 6,899,699
`
`U.S. Patent No. 8,684,969
`
`Correa, Ownership of Knowledge – the Role of Patents in
`Pharmaceutical R&D, 82 BULLETIN WHO 784 (2004)
`
`McDuff, Thinking Economically About Commercial Success, 9(4)
`LANDSLIDE 37(2017)
`
`Khan, Prescriptions for Trendy Diabetes and Weight-Loss Drugs
`Increased Over 2,000% Since 2019, KOMODO (Feb. 17, 2023)
`
`Gordon, The Share of Ozempic Users with Diabetes has Decreased
`Over Time, Indicating Increased Off-label Use – HCCI, HEALTH
`CARE COST INSTITUTE, https://healthcostinstitute.org/hcci-originals-
`dropdown/topics/diabetes-and-insulin/ozempic-users-with-
`diabetes-have-decreased-over-time-indicating-increased-off-label-
`use
`
`Small Business Assistance: Frequently Asked Questions for New
`Drug Product Exclusivity, FDA.GOV,
`https://www.fda.gov/drugs/cder-small-business-industry-
`assistance-sbia/small-business-assistance-frequently-asked-
`questions-new-drug-product-exclusivity
`
`Frequently Asked Questions on Patents and Exclusivity, FDA.GOV,
`https://www.fda.gov/drugs/development-approval-process-
`drugs/frequently-asked-questions-patents-and-exclusivity
`
`McPhillips, CNN Exclusive: Prescriptions for Popular Diabetes
`and Weight-Loss Drugs Soared, but Access is Limited for Some
`Patients, CNN HEALTH (Sept. 27, 2023)
`
`Novo Nordisk Annual Report 2023
`
`Novo Nordisk Annual Report 2007
`
`- 15 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1179
`
`Corr, The Pathway from Idea to Regulatory Approval: Examples
`for Drug Development, NIH
`
`David, Commercial Success: Economic Principles Applied to
`Patent Litigation, in, ECONOMIC DAMAGES IN INTELLECTUAL
`PROPERTY: A HANDS-ON GUIDE TO LITIGATION 159 (2006)
`
`Type 2 Diabetes, MEDLINE PLUS,
`https://medlineplus.gov/ency/article/000313.htm
`
`Ingram, More than 4,000 ads for Ozempic-style Drugs Found
`Running on Instagram and Facebook, NBC NEWS (June 15, 2023)
`
`U.S. Patent No. 7,762,994
`
`Trilliant Health, 2023 Trends Shaping the Health Economy
`
`Ozempic Statistics and Trends in 2024, TRACKDRUGS,
`https://trackdrugs.com/Ozempic-statistics
`
`Gilbert, Prescriptions for Ozempic and Similar Drugs have
`Skyrocketed, Data Shows, WASHINGTON POST (Sept. 27, 2023)
`
`U.S. Patent No. 8,579,869
`
`1180
`
`1181
`
`1182
`
`1183
`
`1184
`
`1185
`
`1186
`
`1187
`
`1188
`
`U.S. Patent No. 9,108,002
`
`1189
`
`1190
`
`1191
`
`1192
`
`1193
`
`Gilbert, Insurers Clamping Down on Doctors who Prescribe
`Ozempic for Weight Loss, WASHINGTON POST
`
`Novo Nordisk Q1 2022 Earnings Call Transcript (Apr. 29, 2022)
`
`U.S. Patent No. 9,457,154
`
`U.S. Patent No. 9,132,239
`
`U.S. Patent No. 8,672,898
`
`1194
`
`U.S. Patent No. 8,920,383
`
`- 16 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`DESCRIPTION
`
`1195
`
`1196
`
`1197
`
`1198
`
`1199
`
`1200
`
`1201
`
`1202
`
`1203
`
`1204
`
`1205
`
`1206
`
`1207
`
`1208
`
`1209
`
`1210
`
`1211
`
`1212
`
`U.S. Patent No. 9,687,611
`
`U.S. Patent No. 9,616,180
`
`U.S. Patent No. 10,376,652
`
`U.S. Patent No. 11,097,063
`
`U.S. Patent No. 9,861,757
`
`U.S. Patent No. 9,775,953
`
`U.S. Patent No. 9,486,588
`
`U.S. Patent No. 11,446,443
`
`U.S. Patent No. 11,311,679
`
`U.S. Patent No. 10,220,155
`
`U.S. Patent No. 10,357,616
`
`Wegovy prescribing information (July 2023)
`
`Weintraub, These 15 Metro Areas Saw Biggest Jumps in Ozempic
`Use. They Might not be Where you Expect., USA TODAY (Oct. 25,
`2023)
`
`MPEP 1801
`
`WO 2005/049061
`
`Walker, Objective Evidence of Nonobviousness: The Elusive Nexus
`Requirement (Part I), 69 JPTOS 175(1987)
`
`U.S. Patent No. RE46,363
`
`Rawshani, Mortality and Cardiovascular Disease in Type 1 and
`Type 2 Diabetes, 376 NEW ENGLAND J. MED. 1407 (2017).
`
`- 17 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1213
`
`1214
`
`1215
`
`1216
`
`1217
`
`1218
`
`1219
`
`1220
`
`1221
`
`1222
`
`1223
`
`DESCRIPTION
`
`Gore, Diabetes Mellitus and Trends in Hospital Survival After
`Myocardial Infarction, 1994 to 2006, Data From the National
`Registry of Myocardial Infarction, 5 CIRC. CARDIOVASC. QUAL.
`OUTCOMES 791 (2012)
`
`Standl, Heart Failure Considerations of Antihyperglycemic
`Medications for Type 2 Diabetes, 118 CIRC. RES. 1830 (2016)
`
`Orasanu, The Pathologic Continuum of Diabetic Vascular Disease,
`53 J. AM. COL. CARDIOLOGY s35 (2009)
`
`Hess, Inflammation and Thrombosis in Diabetes, 105 THROMB
`HAEMOST S43 (2011)
`
`Rawshani, Risk Factors, Mortality, and Cardiovascular Outcomes
`in Patients with Type 2 Diabetes, 379 NEW ENGLAND J. MED. 633
`(2018)
`
`Fox, Update on Prevention of Cardiovascular Disease in Adults
`With Type 2 Diabetes Mellitus in Light of Recent Evidence, 132
`CIRC. 691 (2015)
`
`Grundy, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/
`ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management
`of Blood Cholesterol, 139 CIRC. e1082 (2019)
`
`Gugliano, Benefit of Adding Ezetimibe to Statin Therapy on
`Cardiovascular Outcomes and Safety in Patients With Versus
`Without Diabetes Mellitus, 137 CIRCULATION 1571 (2018)
`
`Sabatine, Efficacy and Safety of Evolocumab in Reducing Lipids
`and Cardiovascular Events, 372 NEW ENG. J. MED. 1500 (2015)
`
`Sabatine, Evolocumab and Clinical Outcomes in Patients with
`Cardiovascular Disease, 376 NEW ENG. J. MED. 1713 (2017)
`
`Emdin, Blood Pressure Lowering in Type 2 Diabetes: A Systematic
`Review and Meta-Analysis, 313 J. AM. MED. ASSOC. 603 (2015)
`
`- 18 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1224
`
`1225
`
`1226
`
`1227
`
`1228
`
`1229
`
`1230
`
`1231
`
`1232
`
`1233
`
`1234
`
`DESCRIPTION
`
`Arnett, 2019 ACC/AHA Guidline on the Primary Prevention of
`Cardiovascular Disease, 140 CIRCULATION e596 (2019)
`
`Pignone, Aspirin for Primary Prevention of Cardiovascular Events
`in People With Diabetes, 121 CIRC. 2694 (2010)
`
`Lathief, Approach to Diabeted Management in Patients with CVD,
`26 TRENDS IN CARDIOVASCULAR MED. 165 (2016)
`
`Kernan, Pioglitazone after Ischemic Stroke or Transient Ischemic
`Attack, 374 NEW ENG. J. MED. 1321 (2016)
`
`Baggio, Biology of Incretins: GLP-1 and GIP, 132
`GASTROENTEROLOGY 2131 (2007)
`
`Nyström, Effects of Glucagon-Like Peptide-1 on Endothelial
`Function in Type 2 Diabetes Patients with Stable Coronary Artery
`Disease, 287 AM J PHYSIOL ENDOCRINOL METAB. E1209 (2004)
`
`Nikolaidis, Effects of Glucagon-Like Peptide-1 in Patients With
`Acute Myocardial Infarction and Left Ventricular Dysfunction
`After Successful Reperfusion, 109 CIRCULATION 962 (2004)
`
`Bose, Glucagon-like Peptide 1 Can Directly Protect the Heart
`Against Ischemia/Reperfusion Injury, 54 DIABETES 146 (2005)
`
`Hirata, Exendin-4 has an Anti-Hypertensive Effect in Salt-Sensitive
`Mice Model, 380 BIOCHEMICAL & BIOPHYSICAL RESEARCH
`COMMC’NS 44 (2009)
`
`Ban, Cardioprotective and Vasodilatory Actions of Glucagon-Like
`Peptide 1 Receptor Are Mediated Through Both Glucagon-Like
`Peptide 1 Receptor–Dependent and –Independent Pathways, 117
`CIRCULATION 2340 (2008)
`
`Noyan-Ashraf, GLP-1R Agonist Liraglutide Activates
`Cytoprotective Pathways and Improves Outcomes After
`Experimental Myocardial Infarction in Mice, 58 DIABETES 975
`(2009)
`
`- 19 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1235
`
`1236
`
`1237
`
`1238
`
`1239
`
`1240
`
`1241
`
`1242
`
`1243
`
`1244
`
`DESCRIPTION
`
`Horton, Weight Loss, Glycemic Control, and Changes in
`Cardiovascular Biomarkers in Patients With Type 2 Diabetes
`Receiving Incretin Therapies or Insulin in a Large Cohort
`Database, 33 DIABETES CARE 1759 (2010)
`
`Okerson, Effects of Exenatide on Systolic Blood Pressure in
`Subjects With Type 2 Diabetes, 23 AM. J. HYPERTENS 334 (2010)
`
`Mannuci, Incretins and the Specific Mechanism of Action of
`Liraglutide, the First Applicable Human Glucagon-Like Peptide I
`Analog in the Treatment of Type 2 Diabetes, 3 J. RECEPTOR,
`LIGAND & CHANNEL RSCH. 105 (2013)
`
`Varanasi, Clinical Use of Liraglutide in Type 2 Diabetes and its
`Effects on Cardiovascular Risk Factors, 18 ENDOCRINE PRACTICE
`140 (2012) (published online on August 19, 2011)
`
`Sesti, Glycemic Control Impact on Body Weight Potential to
`Reduce Cardiovascular Risk, Glucagon-like Peptide 1 Agonists, 34
`DIABETES CARE S272 (2011)
`
`Mells, GLP-1 Analog, Liraglutide, Ameliorates Hepatic Steatosis
`and Cardiac Hypertrophy in C57BL/6J Mice Fed a Western Diet,
`302 AM J PHYSIOL GASTROINTEST LIVER PHYSIOLG225 (2012)
`
`Ussher, Cardiovascular Biology of the Incretin System, 33
`ENDOCRINE REVIEWS 187 (2012)
`
`Marso, Cardiovascular Safety of Liraglutide Assessed in a Patient-
`Level Pooled Analysis of Phase 2–3 Liraglutide Clinical
`Development Studies, 8(3) DIABETES & VASCULAR DISEASE
`RESEARCH, 237 (2011)
`
`Ratner, Cardiovascular Safety of Exenatide BID: An Integrated
`Analysis From Controlled Clinical Trials in Participants with Type
`2 Diabetes, 10 CARDIOVASCULAR DIABETOLOGY 22 (2011)
`
`Siversten, The Effect of Glucagon-Like Peptide 1 on
`Cardiovascular Risk, 9 NAT. REV. CARDIOL. 209 (2012)
`
`- 20 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1245
`
`1246
`
`1247
`
`1248
`
`1249
`
`1250
`
`1251
`
`1252
`
`1253
`
`1254
`
`DESCRIPTION
`
`Sokos, Glucagon-Like Peptide-1 Infusion Improves Left
`Ventricular Ejection Fraction and Functional Status in Patients
`with Chronic Heart Failure, 12 J. CARD. FAIL. 694 (2006)
`
`Smilowitz, Glucagon-Like Peptide 1 Receptor Agonists for
`Diabetes Mellitus, A Role in Cardiovascular Disease, 129
`CIRCULATION 2305 (2014)
`
`Marso, Liraglutide and Cardiovascular Outcomes in Type 2
`Diabetes, 375 NEW ENGLAND J. MED. 311 (2016)
`
`Gerstein, Dulaglutide and Cardiovascular Outcomes in Type 2
`Diabetes (REWIND): A Double-Blind, Randomised Placebo-
`Controlled Trial, 394 LANCET 121 (2019)
`
`Zinman, Empagliflozin, Cadiovascular Outcomes and Mortality in
`Type 2 Diabetes, 373 NEW ENGLAND J. MED. 2117 (2015)
`
`Carbone, The CANVAS Program: Implications of Canagliflozin on
`Reducing Cardiovascular Risk in Patients with Type 2 Diabetes
`Mellitus, 18 CARDIOVASC DIABETOL 64 (2019)
`
`Astrup, Safety, Tolerability and Sustained Weight Loss Over 2
`Years with the Once-Daily Human GLP-1 Analog, Liraglutide, 36
`INTL. J. OBESITY 843 (2012) (published online Aug. 16, 2012).
`
`Ravassa, GLP-1 and Cardioprotection: From Bench to Bedside, 94
`CARDIOVASCULAR RESEARCH 316 (2012) (published ahead of print
`on March 14, 2012).
`
`Reiger, More Than 7 Years of Hindsight: Revisiting the FDA’s
`2008 Guidance on Cardiovascular Outcomes Trials for Type 2
`Diabetes Medications, 34(4) CLINICAL DIABETES J. 173 (2016)
`
`Parks, Weighing Risks and Benefits of Liraglutide – the FDA’s
`Review of a New Antidiabetic Therapy, 362 NEW ENGLAND J. MED.
`774 (2010)
`
`- 21 -
`
`
`
`
`
`EXHIBIT
`NO.
`
`1255
`
`1256
`
`1257
`
`1258
`
`1259
`
`1260
`
`1261
`
`1262
`
`1263
`
`1264
`
`DESCRIPTION
`
`Bucher, The Results of Direct and Indirect Treatment Comparisons
`in Meta-Analysis of Randomized Controlled Trials, 50(6) J. CLIN.
`EPIDEMIOL. 683 (1997)
`
`Southwell, Appropriate use of Prescription Medications for
`Diabetes and Weight Loss Helps to Ensure Patient Access and
`Safety, CIGNA HEALTHCARE NEWSROOM
`
`Diabetes and the Cardiovascular System, in BRAUNWALD’S HEART
`DISEASE, A TEXTBOOK OF CARDIOVASCUALR MEDICINE, Chapter 31
`(12th ed. 2022)
`
`Transcript of April 10, 2024 Deposition of Michael J. Blaha, M.D.,
`M.P.H.
`
`FDA, Guidance for Industry, Diabetes Mellitus – Evaluating
`Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2
`Diabetes (Dec. 2008)
`
`FDA Background Document, Endocrinologic and Metabolic Drugs
`Advisory Committee Meeting (Oct. 24-25, 2018)
`
`Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for
`Improving Glycemic Control, 85 Fed. Reg. 13903 (Mar. 10, 2020)
`
`Trulicity prescribing information (Nov. 2022)
`
`Victoza prescribing information (July 2023)
`
`Jardian
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
